Global Anxiety Disorders and Depression Treatment Market
By Product Type (MAOIs (Monoamine Oxidase inhibitors), Atypical Antipsychotics, Benzodiazepines, Anticonvulsants, Beta-Blockers, SRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TeCAs (Tetracyclic Antidepressants), TCAs (Tricyclic Antidepressants), Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Others), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024
Global anxiety disorders and depression treatment market was valued at US $ XX Mn in 2017 and expected to grow at XX% Compound Annual Growth Rate (CAGR) over 2018 to 2024.
Market Outline: Anxiety Disorders and Depression Treatment Market
Anxiety is a disorder that differ from normal feelings of nervousness or anxiousness. It involves excessive anxiety. Anxiety is a normal reaction to stress. For a patient with anxiety disorder, the anxiety does not lessen but can get worse over the period of time. As per the American Psychiatric Association, Anxiety disorders are the most common of mental disorders and affect nearly 30 percent of adults at some point in their lives. The feelings can interfere with the daily activities. There are various kind of anxiety disorders such as social anxiety disorder and panic disorder.
Market Dynamics: Anxiety Disorders and Depression Treatment Market
Increase in the prevalence of anxiety disorder and depression is majorly driving the growth of the anxiety disorders and depression treatment market. According to the World Health Organization (WHO), in 2017, over 300 million people of all ages globally are suffering from depression, wherein 800,000 people die due to suicide, of which, anxiety disorders and depression are a prime cause. The rising demand for the antidepressants can be attributed to the growth of the market. Growing geriatric population along with mental disorders are adding fuel for the growth of the anxiety disorders and depression treatment market. However, the factors such as patent expiry of the drugs and adoption of the other treatment options such as herbal treatment are expected to hinder the growth of the market. The growing generic drugs are likely to restrain the growth of the anxiety disorders and depression treatment market.
Market Scope: Anxiety Disorders and Depression Treatment Market
Anxiety disorders and depression treatment market is segmented based on the product type and distribution channel
Based on the product type, the market is segmented into the following:
- MAOIs (Monoamine Oxidase inhibitors)
- Atypical Antipsychotics
- Benzodiazepines
- Anticonvulsants
- Beta-Blockers
- SRIs (Selective Serotonin Reuptake Inhibitors)
- SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)
- TeCAs (Tetracyclic Antidepressants)
- TCAs (Tricyclic Antidepressants)
- Others
Based on the distribution channel, the market is segmented into the following:
- Hospital Pharmacies
- Online Pharmacies
- Others
Regional Analysis: Anxiety Disorders and Depression Treatment Market
Geographically, global anxiety disorders and depression treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America anxiety disorders and depression treatment market is the dominant market when compared with that of the other regional markets. According to the National Alliance on Mental Illness, Anxiety disorders are the most common mental health concern in the United States. An estimated 40 million adults in the United States (18%) have an anxiety disorder. Meanwhile, approximately 8% of children and teenagers experience an anxiety disorder. Most people develop symptoms before age 21. According to the Mental Health America, in 2014, 1 in every 5 adults have a mental health condition and the condition is observed to be worsening at rapid rates in youth. The Asia Pacific anxiety disorders and depression treatment market is expected to show a luxurious growth over the forecasted period.
Competition Assessment: Anxiety Disorders and Depression Treatment Market
Some of the players in the global anxiety disorders and depression treatment market include:
- Eli Lilly and Company (U.S)
- Lundbeck A/S (Denmark)
- AstraZeneca (UK)
- Merck and Company, Inc. (U.S)
- Johnson and Johnson (U.S)
- Sanofi-Aventis (France)
- GlaxoSmithKline plc (UK)
- Pfizer, Inc. (U.S)
Key Features of the Report:
- The report covers exhaustive regional information, that includes North America (the USA and Canada), Europe (Germany, France, Italy, UK, Spain, Russia, Poland and Rest of Europe), Asia-Pacific (Japan, China, India, Australia & New Zealand, ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others), South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentian, Venezula, and Rest of Latin America), and Middle East and Africa (Gulf Cooperation Council (GCC) Countries, Israel, South Africa, and Rest of Middle East and Africa)
- The report provides granular level information about the market size, regional market share, historic market (2013-2017) and forecast (2018-2024)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
